Zygote Ventures

Zygote Ventures is a privately held seed/angel venture capital fund. Zygote typically invests first, or very early, in innovative enterprises, most often technology, biotech, and agriculture. As a privately held “angel” investor, Zygote Ventures falls somewhere between an entrepreneur and a traditional venture capital fund. Most VC’s are limited partnerships, investing “other people’s money” and earning much of their profit as fees and carry. In contrast, Zygote invests only its principal’s money, and therefore earns no fees, profiting only from an increase in the value of the enterprise. This means that our interests are very closely aligned with the entrepreneur’s. Without limited partners, Zygote can be less risk-averse than most VCs. Because there is no pressure to do a certain number of deals, or to invest a fixed-size fund, Zygote can choose to partner with those opportunities where we can provide real value. At the same time, as an angel investor Zygote is very complementary with more traditional VC, helping to bring a company to readiness for a larger venture round if more capital is required, or co-investing with VCs and/or other angels in cases where we bring value to the enterprise.

Zygote Ventures, established in 1981 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Seed investments across Software, Green Building, Biomass Energy, Biofuel, Chemical, Financial Services, Finance, Lending, Asset Management, Enterprise Software. The organization boasts a portfolio of 12 investments, with an average round size of $12.3M and 3 successful exits. Their recent investments include GreenWizard, Solazyme, Morgan Stanley, NexSteppe, Braemar Energy Ventures. The highest investment round they participated in was $7.9B. Among their most notable exits are GreenWizard and Solazyme. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.